Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

NCT01215578 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

33

Enrollment

OTHER

Sponsor class

Stopped lack of recruitement

Conditions

Neuroendocrine Tumors
Pancreatic Neoplasms
Advanced Disease
Sunitinib

Interventions

DRUG: Sutent

Sponsor

Assistance Publique - Hôpitaux de Paris